Zevra Therapeutics Files Preliminary Proxy

Core Viewpoint - Zevra Therapeutics is preparing for its 2025 Annual Meeting of Stockholders, where it has nominated two incumbent directors for re-election while facing a proxy contest initiated by a stockholder proposing alternative candidates. The company emphasizes its progress and strategic focus, urging stockholders to support its current board. Group 1: Company Developments - Zevra Therapeutics filed its preliminary proxy statement with the SEC for the 2025 Annual Meeting, indicating that stockholders do not need to take action at this time [2] - The Board has nominated Wendy L. Dixon, Ph.D., and Tamara A. Favorito for re-election, both of whom bring over 70 years of combined life sciences experience [3][4] - The company has launched its first two products since the last annual meeting and has a cash runway extending into 2029, bolstered by a $150 million sale of a Priority Review Voucher [7] Group 2: Proxy Contest and Board Dynamics - Stockholder Daniel J. Mangless is proposing the election of two candidates, which the Zevra Board believes could disrupt its strategic plan and recommends stockholders reject these efforts [5][8] - The Board asserts that it has made significant progress in transforming the company into a more efficient organization focused on creating value for patients and stockholders [6][9] - Zevra's management has engaged with Mr. Mangless to avoid a costly proxy contest, emphasizing the importance of maintaining board stability for continued execution of its strategic plan [8][9]